{{Drugbox
| Watchedfields = changed
| verifiedrevid = 464213227
| IUPAC_name = ''N''-[4-oxo-2-(1''H''-tetrazol-5-yl)-4''H''-chromen-8-yl]-4-(4-phenylbutoxy)benzamide
| image = Pranlukast.svg

<!--Clinical data-->
| tradename = Onon (オノン)
| Drugs.com = {{drugs.com|international|pranlukast}}
| pregnancy_category =  
| legal_status =  
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism = [[Liver|Hepatic]] (mainly [[CYP3A4]])<ref name = Nakade>{{cite journal |vauthors=Nakade S, Ueda S, Ohno T, Nakayama K, Miyata Y, Yukawa E, Higuchi S | title = Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma. | journal = Drug Metab Pharmacokinet | volume = 21 | issue = 2 | pages = 133–9 | year = 2006 | pmid = 16702733 | url = http://www.jstage.jst.go.jp/article/dmpk/21/2/21_133/_article | doi = 10.2133/dmpk.21.133}}</ref>
| elimination_half-life = 1.5 hours<ref name = Nakade/>
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 3634
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 103177-37-3
| ATC_prefix = R03
| ATC_suffix = DC02
| PubChem = 4887
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01411
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4718
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = TB8Z891092
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 21333

<!--Chemical data-->
| C=27 | H=23 | N=5 | O=4 
| molecular_weight = 481.503 g/mol
| smiles = O=C(c2ccc(OCCCCc1ccccc1)cc2)Nc5cccc3c5O/C(=C\C3=O)c4nnnn4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = NBQKINXMPLXUET-UHFFFAOYSA-N
}}
'''Pranlukast''' (brand name '''Onon''', '''オノン''') is a cysteinyl [[Leukotriene receptor antagonist|leukotriene receptor-1 antagonist]].  This drug works similarly to [[Merck & Co.]]'s [[montelukast]] (Singulair). It is widely used in Japan.

Medications of this class, which go under a variety of names according to whether one looks at the American, British or European system of nomenclature, have as their primary function the antagonism of [[bronchospasm]] caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered [[allergen]]s.<ref name="SinghTandon2013">{{cite journal|last1=Singh|first1=Rakesh Kumar|last2=Tandon|first2=Ruchi|last3=Dastidar|first3=Sunanda Ghosh|last4=Ray|first4=Abhijit|title=A review on leukotrienes and their receptors with reference to asthma|journal=Journal of Asthma|volume=50|issue=9|year=2013|pages=922–931|issn=0277-0903|doi=10.3109/02770903.2013.823447|pmid=23859232}}</ref>

Medications of this group are normally used as an adjunct to the standard therapy of inhaled steroids with inhaled [[Long acting beta-adrenoceptor agonist|long-]] and/or short-acting [[Beta2-adrenergic receptor agonist|beta-agonist]]s. There are several similar medications in the group; all appear to be equally effective.

==References==

{{Reflist|2}}

{{Asthma and copd rx}}
{{Leukotrienergics}}

[[Category:Leukotriene antagonists]]
[[Category:Tetrazoles]]
[[Category:Chromones]]
[[Category:Benzamides]]
[[Category:Phenol ethers]]